Pfizer is a publicly listed company tracked for investment-relevant business developments.
Pfizer invested $80B+ in acquisitions (led by Seagen for ADC tech and MyThera for obesity) while restructuring R&D to improve focus, raising phase 2 success rates from 20% to 50%+ and regulatory success to ~95%, positioning for sustained growth after COVID revenue dropped from $56B to $6B.